S1 Data -

Objective
This study evaluated the effect of the systemic immune-inflammation index/albumin ratio (SII/ALB) on the prognosis of immunotherapy-treated patients receiving opioids.
Methods
A retrospective analysis was conducted of 185 immunotherapy-treated patients who received opioids at Xuzhou Central Hospital from 01/09/2021 to 01/09/2023. The results of related clinical data were collected during the week before the cancer patients received immunotherapy. The SII/ALB cut-off value was determined, and the relationship between the SII/ALB and clinical pathological parameters was analyzed using the chi-square test. The effect of the SII/ALB on progression-free survival (PFS) was examined using Kaplan-Meier curves and the Cox proportional hazard model.
Result
The SII/ALB cut-off value was 20.86, and patients were divided into low (SII/ALB ≤ 20.86) and high (SII/ALB > 20.86) SII/ALB groups. Adverse reactions (hazard ratio [HR] = 0.108; 95% confidence interval [CI]: 0.061–0.192, P < 0.001) and the SII/ALB (HR = 0.093; 95% CI: 0.057–0.151, P < 0.001) were independent prognostic factors for PFS. Compared with the high SII/ALB group, the low SII/ALB group had longer PFS after opioid treatment (12.2 vs. 5.2 months, P < 0.001).
Conclusion
The SII/ALB is a potentially important prognostic parameter in immunotherapy-treated patients receiving opioids.

研究目的
本研究旨在评估全身免疫炎症指数与白蛋白比值（systemic immune-inflammation index/albumin ratio, SII/ALB）对接受阿片类药物治疗的免疫治疗患者预后的影响。

研究方法
本研究对2021年9月1日至2023年9月1日期间于徐州市中心医院接受阿片类药物治疗的185例免疫治疗患者开展回顾性分析。收集癌症患者接受免疫治疗前1周内的相关临床数据。确定SII/ALB的截断值，并采用卡方检验分析SII/ALB与临床病理参数之间的关联。采用Kaplan-Meier曲线及Cox比例风险模型分析SII/ALB对无进展生存期（progression-free survival, PFS）的影响。

研究结果
本研究确定SII/ALB的截断值为20.86，据此将患者分为低SII/ALB组（SII/ALB ≤20.86）与高SII/ALB组（SII/ALB >20.86）。不良反应（风险比[HR]=0.108；95%置信区间[CI]：0.061~0.192，P<0.001）与SII/ALB（HR=0.093；95%CI：0.057~0.151，P<0.001）均为PFS的独立预后因素。与高SII/ALB组相比，低SII/ALB组患者接受阿片类药物治疗后的无进展生存期更长（12.2个月 vs 5.2个月，P<0.001）。

研究结论
SII/ALB可作为接受阿片类药物治疗的免疫治疗患者潜在的重要预后评估参数。